Document is current
Any future updates will be listed below
-
Authors
Chattopadhyay, Chandrani https://orcid.org/0000-0001-8258-2953
Roszik, Janos https://orcid.org/0000-0002-4561-6170
Bhattacharya, Rajat
Alauddin, Md
Mahmud, Iqbal
Yadugiri, Sirisha
Ali, Mir Mustafa
Khan, Fatima S.
Prabhu, Varun Vijay
Lorenzi, Philip L. https://orcid.org/0000-0003-0385-7774
Wei, Bo https://orcid.org/0000-0001-5573-5715
Burton, Elizabeth
Morey, Rohini R.
Lazcano, Rossana
Davies, Michael A. https://orcid.org/0000-0002-0977-0912
Patel, Sapna P. https://orcid.org/0000-0003-1339-1517
Grimm, Elizabeth A.
- License Information
-
More Information
Article History
Received: 28 March 2024
Revised: 11 September 2024
Accepted: 23 September 2024
First Online: 11 October 2024
Competing interests
: VVP is an employee and stockholder of Chimerix/Oncoceutics. MAD has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, and he has been the PI of research grants to The University of Texas MD Anderson Cancer Center by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma.
: All procedures performed in obtaining tissues from human participants were in accordance with the ethical standards of The University of Texas MD Anderson Cancer Center and ethical tenets in the Declaration of Helsinki. All the human tissues were obtained and banked under The University of Texas MD Anderson Cancer Center approved IRB protocol. We attest that all human tissues were obtained with informed consent from subjects involved. All animal studies and procedures were performed in accordance with The University of Texas at MD Anderson Cancer Center’s approved IACUC protocol following relevant guidelines and regulations.
: All authors have been provided with a copy of the manuscript and have reviewed prior to submission and have provided consent to publication.
